Hong Kong Children's Hospital receives smooth delivery of cord blood haematopoietic stem cell unit from Mainland for patient treatment
***************************************************************
The following is issued on behalf of the Hospital Authority:
The Hong Kong Children's Hospital (HKCH) has been treating a 5-year-old girl who suffers from thalassaemia. The clinical team had planned to perform a haematopoietic stem cell transplant for the patient, and during the process, it was noted that her relative has a cord blood unit stored in a cord blood bank in Guangzhou. Putting the patient's treatment as the priority, the clinical team communicated with the cord blood bank concerned, which included understanding the details of the cord blood unit, as well as regulations and procedures for cross-boundary transportation. The clincial team has rendered full facilitation during the process.
Upon notification by HKCH, the Hospital Authority Head Office informed relevant government departments about the transfer and transplant arrangements of this case per the usual mechanism. The Hospital Authority has ensured the transfer and transplant processes comply with related regulations in Hong Kong and the Mainland, and requested that no commercial considerations would be involved.
The cord blood unit concerned arrived as planned today (July 25) at the HKCH stem cell transplant laboratory, where it is now being stored according to established procedures. The clinical team will perform the transplant for the patient at an appropriate time according to the treatment plan and her clinical condition.
HKCH expresses gratitude to all Hong Kong and Mainland units involved in the process for their support and facilitation in bringing hope for the patient's treatment.
HKCH is the only centre in Hong Kong to perform haematopoietic stem cell transplants for children. About 40 to 50 transplants are performed each year, including several thalassaemia cases. Sources of haematopoietic stem cells include bone marrow, peripheral blood stem cells and cord blood. Based on their individual situations, patients can receive an autologous or allogeneic transplant, using haematopoietic stem cells from their siblings, parents or unrelated donors.
Ends/Thursday, July 25, 2024
Issued at HKT 20:00
NNNN